Floatz logo

Gtx-006

Invasive Breast Carcinoma

Fred Hutchinson Cancer CenterPhase 4 / ApprovedDormant
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
89/ 100

Competitive context

59 Active assets in the Invasive Breast Carcinoma cohort.

Asset / SponsorPhaseRating
TAMOXIFEN
University of California, San Francisco
Phase 4BBB
Letrozole
Emory University
Phase 4BBB
EXEMESTANE
University of California, San Francisco
Phase 4BBB
Arimidex
Jonsson Comprehensive Cancer Center
Phase 4BBB
FULVESTRANT
Massachusetts General Hospital
Phase 2BB

View all 50 →

Same molecule, other indications

Gtx-006 is also rated in:

prostate intraepithelial neoplasiaDormant
BB
Indicative ·
68 / 100
View asset →
Her2-receptor negative breast cancerDormant
BB
Indicative ·
65 / 100
View asset →
breast carcinoma in situDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →